Tadayoshi Hashimoto

548 total citations
39 papers, 277 citations indexed

About

Tadayoshi Hashimoto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Tadayoshi Hashimoto has authored 39 papers receiving a total of 277 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 12 papers in Surgery. Recurrent topics in Tadayoshi Hashimoto's work include Gastric Cancer Management and Outcomes (17 papers), Colorectal Cancer Treatments and Studies (13 papers) and Cancer Genomics and Diagnostics (8 papers). Tadayoshi Hashimoto is often cited by papers focused on Gastric Cancer Management and Outcomes (17 papers), Colorectal Cancer Treatments and Studies (13 papers) and Cancer Genomics and Diagnostics (8 papers). Tadayoshi Hashimoto collaborates with scholars based in Japan, United States and Italy. Tadayoshi Hashimoto's co-authors include Yukinori Kurokawa, Yuichiro� Doki, Masaki Mori, Tsuyoshi Takahashi, Makoto Yamasaki, Yasuhiro Miyazaki, Koji Tanaka, Kiyokazu Nakajima, Tomoki Makino and Masaaki Motoori and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and BMJ Open.

In The Last Decade

Tadayoshi Hashimoto

33 papers receiving 276 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tadayoshi Hashimoto Japan 10 170 161 95 38 35 39 277
Maoxing Liu China 12 186 1.1× 126 0.8× 146 1.5× 31 0.8× 69 2.0× 31 325
Radek Vrba Czechia 8 160 0.9× 154 1.0× 137 1.4× 64 1.7× 28 0.8× 48 309
Jun-Peng Lin China 9 169 1.0× 125 0.8× 162 1.7× 41 1.1× 18 0.5× 23 288
Giuseppe Tirino Italy 9 125 0.7× 108 0.7× 161 1.7× 75 2.0× 38 1.1× 24 297
Luca Pompella Italy 9 125 0.7× 106 0.7× 164 1.7× 74 1.9× 37 1.1× 25 302
R Aujeský Czechia 9 200 1.2× 224 1.4× 86 0.9× 40 1.1× 50 1.4× 48 352
Yoshiki Horie Japan 7 161 0.9× 103 0.6× 180 1.9× 26 0.7× 13 0.4× 30 266
Ryuichiro Sawada Japan 10 121 0.7× 192 1.2× 164 1.7× 29 0.8× 13 0.4× 51 301
Chun‐Jung Lin Taiwan 9 98 0.6× 122 0.8× 67 0.7× 24 0.6× 20 0.6× 15 362
Hajime Ushigome Japan 10 94 0.6× 106 0.7× 113 1.2× 26 0.7× 25 0.7× 30 225

Countries citing papers authored by Tadayoshi Hashimoto

Since Specialization
Citations

This map shows the geographic impact of Tadayoshi Hashimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tadayoshi Hashimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tadayoshi Hashimoto more than expected).

Fields of papers citing papers by Tadayoshi Hashimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tadayoshi Hashimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tadayoshi Hashimoto. The network helps show where Tadayoshi Hashimoto may publish in the future.

Co-authorship network of co-authors of Tadayoshi Hashimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Tadayoshi Hashimoto. A scholar is included among the top collaborators of Tadayoshi Hashimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tadayoshi Hashimoto. Tadayoshi Hashimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aoki, Yu, Tadayoshi Hashimoto, Nobuyuki Takahashi, et al.. (2025). Clinical Significance of Extrachromosomal DNA in FGFR2 -Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience. JCO Precision Oncology. 9(9). e2500033–e2500033.
2.
Yajima, Shugo, Shin Kobayashi, Tadayoshi Hashimoto, & Hitoshi Masuda. (2025). Physical activity in older cancer patients: evidence and clinical implications. Frontiers in Oncology. 15. 1613268–1613268.
3.
Hashimoto, Tadayoshi, Yoshiaki Nakamura, Eiji Oki, et al.. (2024). Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. International Journal of Clinical Oncology. 29(5). 495–511. 10 indexed citations
4.
Nakayama, Izuma, Manabu Ohashi, Junki Mizusawa, et al.. (2024). Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).. Journal of Clinical Oncology. 42(3_suppl). TPS418–TPS418. 1 indexed citations
5.
Hashimoto, Tadayoshi, Yoshiaki Nakamura, Saori Mishima, et al.. (2024). Whole‐transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. Cancer Science. 115(5). 1622–1633. 9 indexed citations
6.
Hashimoto, Tadayoshi, Satoshi Maruyama, Yasumasa Takii, et al.. (2023). A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006. Future Oncology. 19(28). 1897–1904.
7.
Hashimoto, Tadayoshi, Satoshi Otsu, Shuichi Hironaka, et al.. (2023). Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. Future Oncology. 19(23). 1593–1600. 4 indexed citations
8.
9.
10.
Hashimoto, Tadayoshi, Izuma Nakayama, Manabu Ohashi, et al.. (2023). Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer. Future Oncology. 19(32). 2147–2155. 9 indexed citations
11.
Ouchi, Akira, Ryo Sadachi, Shunsuke Tsukamoto, et al.. (2023). Prognostic Relevance of Primary Tumor Sidedness in Early-stage Colorectal Cancer. Annals of Surgery. 279(2). 283–289. 3 indexed citations
12.
Hashimoto, Tadayoshi, Yukinori Kurokawa, Tsuyoshi Takahashi, et al.. (2019). Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Gastric Cancer. 22(4). 785–792. 55 indexed citations
13.
Hashimoto, Tadayoshi, Yukinori Kurokawa, Noriko Wada, et al.. (2019). Clinical significance of chromatin remodeling factor CHD5 expression in gastric cancer. Oncology Letters. 19(1). 1066–1073. 8 indexed citations
14.
Sugase, Takahito, Tomoki Makino, Makoto Yamasaki, et al.. (2018). Histological changes of superficial esophageal squamous cell carcinoma after preoperative chemotherapy. Esophagus. 15(4). 263–271. 6 indexed citations
15.
Nakamura, Yuki, Köichi Toda, Teruya Nakamura, et al.. (2017). Curative surgery for gastric cancer in a patient with an implantable left ventricular assist device. Journal of Artificial Organs. 20(2). 170–173. 10 indexed citations
16.
Kagawa, Yoshinori, Takeshi Kato, Yasufumi Sato, et al.. (2014). [A case of appendiceal intussusception induced by appendiceal carcinoma].. PubMed. 41(12). 1628–30. 1 indexed citations
17.
Matsunaga, Sachihiro, et al.. (2013). ASURA (PHB2) Interacts with Scc1 through Chromatin. Cytogenetic and Genome Research. 139(4). 225–233. 2 indexed citations
18.
Hashimoto, Tadayoshi, Yoshiaki Kajiyama, Yuko Tsutsumi‐Ishii, Isao Nagaoka, & Masahiko Tsurumaru. (2008). Circulating micrometastases of esophageal cancer detected by carcinoembryonic antigen mRNA reverse transcriptase-polymerase chain reaction: clinical implications. Diseases of the Esophagus. 21(8). 690–696. 11 indexed citations
19.
Ito, Isao, et al.. (1999). Vibrio vulnificus Infection: Clinical and Bacteriological Analysis of Four Cases. Kansenshogaku zasshi. 73(2). 149–155. 2 indexed citations
20.
Ashizawa, Tetsuo, et al.. (1996). Hepatic arterial infusion chemotherapy after partial hepatectomy of liver metastases in colorectal cancer. 9(1). 30–32.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maoxing Liu Breakdown of academic impact, for papers by Radek Vrba Breakdown of academic impact, for papers by Jun-Peng Lin Breakdown of academic impact, for papers by Giuseppe Tirino Breakdown of academic impact, for papers by Luca Pompella Breakdown of academic impact, for papers by R Aujeský Breakdown of academic impact, for papers by Yoshiki Horie Breakdown of academic impact, for papers by Ryuichiro Sawada Breakdown of academic impact, for papers by Chun‐Jung Lin Breakdown of academic impact, for papers by Hajime Ushigome
Rankless by CCL
2026